And another one bites the dust.... Glad I didn't go into this trial, which I looked at closely.

A futility study showed in several analyses that both doses of the drug that were tested (15 mg and 45 mg) were futile at slowing disease progression, Tanya Simuni, MD, of Northwestern University, and colleagues reported online in the Lancet Neurology.

"Our results show that pioglitazone is unlikely to be efficacious as a disease-modifying intervention in early Parkinson's and therefore is not recommended for further testing for that indication," they wrote. "Although our negative results are disappointing, the design of this futility study is an example of a useful and efficient study design that can exclude a compound unlikely to be successful in larger and more costly phase III studies."

http://www.medpagetoday.com/Neurolog...sDisease/52347

Keep in mind, this is another drug that proved quite successful in curing PD for Mickey Mouse in pre-clinical research.